Page 2 - Precertification Pilot News Today

Pear Therapeutics and Prescryptive Health Announce Formulary Coverage for Prescription Digital Therapeutics reSET® & reSET-O® for the Treatment of Substance and Opioid Use Disorders By Staff 2 seconds ago Prescryptive Health, a health intelligence platform focused on improving the prescription drug market and the pharmacy experience, teams with Pear to make innovative prescription digital therapeutics (PDTs) accessible to its members in recovery. Prescryptive Health will offer and administe...

Company adds a leading national Integrated Delivery Network (IDN) as a strategic investor. The financing supports Pear’s continued efforts to expand patient access for its portfolio of Prescription Digital Therapeutics (PDTs), including reSET®, reSET-O® and Somryst® treating addiction and insomnia conditions, respectively. BOSTON & SAN FRANCISCO–(BUSINESS WIRE)–Pear Therapeutics, Inc., (“Pear” or the “Company”) today announced the second closing of its Series D financing. The s...

etectRx Announces Agreement to Advance Digital Sensors for Medication Adherence in Combination with Prescription Digital Therapeutics News provided by Share this article Share this article GAINESVILLE, Fla., Jan. 14, 2021 /PRNewswire/ -- Digital health company, etectRx, Inc., announced today that it has entered into an agreement with Pear Therapeutics, Inc. to develop up to two product candidates in the Central Nervous System (CNS) space combining Prescription Digital Therapeutics (PDTs) and ...

Pear Therapeutics Announces Publication of Economic Analysis Assessing the Cost-Effectiveness of reSET-O® in Treating Opioid Use Disorder (OUD) By Staff 4 months ago reSET-O® is the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for patients with opioid use disorder (OUD). New economic analysis showed reSET-O to be cost-effective compared to treatment-as-usual alone over 12 weeks, and to have economic dominance when contingency management (CM) was included as part of t...